These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 19470238)
1. Development of human tumor necrosis factor-alpha muteins with improved therapeutic potential. Jang SH; Kim H; Cho KH; Shin HC BMB Rep; 2009 May; 42(5):260-4. PubMed ID: 19470238 [TBL] [Abstract][Full Text] [Related]
2. In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Cooke SP; Pedley RB; Boden R; Begent RH; Chester KA Bioconjug Chem; 2002; 13(1):7-15. PubMed ID: 11792173 [TBL] [Abstract][Full Text] [Related]
3. Human pro-tumor necrosis factor is a homotrimer. Tang P; Hung M-C ; Klostergaard J Biochemistry; 1996 Jun; 35(25):8216-25. PubMed ID: 8679576 [TBL] [Abstract][Full Text] [Related]
4. Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship. Zhang XM; Weber I; Chen MJ J Biol Chem; 1992 Nov; 267(33):24069-75. PubMed ID: 1331108 [TBL] [Abstract][Full Text] [Related]
5. Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Kuroda K; Miyata K; Shikama H; Kawagoe T; Nishimura K; Takeda K; Sakae N; Kato M Int J Cancer; 1995 Sep; 63(1):152-7. PubMed ID: 7558445 [TBL] [Abstract][Full Text] [Related]
6. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704 [TBL] [Abstract][Full Text] [Related]
7. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo. Yan Z; Zhao N; Wang Z; Li B; Bao C; Shi J; Han W; Zhang Y Cytotherapy; 2006; 8(4):415-23. PubMed ID: 16923618 [TBL] [Abstract][Full Text] [Related]
8. A novel recombinant tumor necrosis factor-alpha mutant with increased anti-tumor activity and lower toxicity. Nakamura S; Kato A; Masegi T; Fukuoka M; Kitai K; Ogawa H; Ichikawa Y; Maeda M; Watanabe N; Kohgo Y Int J Cancer; 1991 Jul; 48(5):744-8. PubMed ID: 1649139 [TBL] [Abstract][Full Text] [Related]
9. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Sato T; Yamauchi N; Sasaki H; Takahashi M; Okamoto T; Sakamaki S; Watanabe N; Niitsu Y Cancer Res; 1998 Apr; 58(8):1677-83. PubMed ID: 9563482 [TBL] [Abstract][Full Text] [Related]
10. Crystal structure of TNF-alpha mutant R31D with greater affinity for receptor R1 compared with R2. Reed C; Fu ZQ; Wu J; Xue YN; Harrison RW; Chen MJ; Weber IT Protein Eng; 1997 Oct; 10(10):1101-7. PubMed ID: 9488135 [TBL] [Abstract][Full Text] [Related]
11. Efficiency of recombinant human TNF in human cancer therapy. Lejeune FJ; Liénard D; Matter M; Rüegg C Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058 [TBL] [Abstract][Full Text] [Related]
12. Novel muteins of human tumor necrosis factor alpha. Ito R; Matsumoto H; Uchida K; Kubo T; Tsukii Y; Endo T; Kaji A Biochim Biophys Acta; 1991 Apr; 1096(3):245-52. PubMed ID: 2018798 [TBL] [Abstract][Full Text] [Related]
13. Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I. Hildt E; Oess S J Exp Med; 1999 Jun; 189(11):1707-14. PubMed ID: 10359574 [TBL] [Abstract][Full Text] [Related]
14. Functionality of intrinsic disorder in tumor necrosis factor-α and its receptors. Uversky VN; El-Baky NA; El-Fakharany EM; Sabry A; Mattar EH; Uversky AV; Redwan EM FEBS J; 2017 Nov; 284(21):3589-3618. PubMed ID: 28746777 [TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of human tumor necrosis factor-alpha. Shin HC; Cho KH Biotechnol Lett; 2005 Jan; 27(2):107-12. PubMed ID: 15703873 [TBL] [Abstract][Full Text] [Related]
16. Modulation of death receptor pathways in oncology. de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748 [TBL] [Abstract][Full Text] [Related]
17. Structure-activity studies of human tumour necrosis factors. Van Ostade X; Tavernier J; Fiers W Protein Eng; 1994 Jan; 7(1):5-22. PubMed ID: 8140094 [TBL] [Abstract][Full Text] [Related]
18. BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Gordon NC; Pan B; Hymowitz SG; Yin J; Kelley RF; Cochran AG; Yan M; Dixit VM; Fairbrother WJ; Starovasnik MA Biochemistry; 2003 May; 42(20):5977-83. PubMed ID: 12755599 [TBL] [Abstract][Full Text] [Related]
19. Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells. Corti A; Gasparri A; Sacchi A; Curnis F; Sangregorio R; Colombo B; Siccardi AG; Magni F Cancer Res; 1998 Sep; 58(17):3866-72. PubMed ID: 9731496 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells. Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]